$SAGE
Sage Therapeutics, Inc.

2021 Q1 Form 10-Q Financial Statement

#000156459021022988 Filed on May 04, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q1
Revenue $1.600M $2.286M
YoY Change -30.01% 391.61%
Cost Of Revenue $200.0K $200.0K
YoY Change 0.0%
Gross Profit $1.400M $2.100M
YoY Change -33.33%
Gross Profit Margin 87.5% 91.86%
Selling, General & Admin $39.80M $70.10M
YoY Change -43.22% -16.47%
% of Gross Profit 2842.86% 3338.1%
Research & Development $58.10M $63.61M
YoY Change -8.66% -26.38%
% of Gross Profit 4150.0% 3029.05%
Depreciation & Amortization $2.600M $700.0K
YoY Change 271.43% 75.0%
% of Gross Profit 185.71% 33.33%
Operating Expenses $97.90M $133.9M
YoY Change -26.89% -21.38%
Operating Profit -$96.51M -$131.6M
YoY Change -26.68% -22.51%
Interest Expense $708.0K $4.729M
YoY Change -85.03% -26.59%
% of Operating Profit
Other Income/Expense, Net $35.00K $155.0K
YoY Change -77.42% 3775.0%
Pretax Income -$95.80M -$126.7M
YoY Change -24.39% -22.46%
Income Tax
% Of Pretax Income
Net Earnings -$95.76M -$126.7M
YoY Change -24.44% -22.44%
Net Earnings / Revenue -5985.25% -5544.18%
Basic Earnings Per Share -$2.44
Diluted Earnings Per Share -$1.640M -$2.44
COMMON SHARES
Basic Shares Outstanding 58.37M 51.91M
Diluted Shares Outstanding 58.37M 51.91M

Balance Sheet

Concept 2021 Q1 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.005B $875.1M
YoY Change 129.14% -35.35%
Cash & Equivalents $900.5M $201.8M
Short-Term Investments $1.105B $673.3M
Other Short-Term Assets $23.10M $25.50M
YoY Change -9.41% 25.62%
Inventory
Prepaid Expenses
Receivables $24.80M
Other Receivables $0.00
Total Short-Term Assets $2.052B $898.2M
YoY Change 128.44% -34.51%
LONG-TERM ASSETS
Property, Plant & Equipment $4.173M $8.684M
YoY Change -51.95% 33.33%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $4.700M $3.694M
YoY Change 27.23% -15.62%
Total Long-Term Assets $28.80M $46.74M
YoY Change -38.38% -9.04%
TOTAL ASSETS
Total Short-Term Assets $2.052B $898.2M
Total Long-Term Assets $28.80M $46.74M
Total Assets $2.081B $945.0M
YoY Change 120.19% -33.59%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.300M $7.910M
YoY Change -58.28% -41.65%
Accrued Expenses $51.42M $52.18M
YoY Change -1.46% 9.5%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $62.00M $70.36M
YoY Change -11.88% 2.87%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $15.40M $25.40M
YoY Change -39.37% -27.43%
Total Long-Term Liabilities $15.40M $25.40M
YoY Change -39.37% -27.43%
TOTAL LIABILITIES
Total Short-Term Liabilities $62.00M $70.36M
Total Long-Term Liabilities $15.40M $25.40M
Total Liabilities $77.40M $95.80M
YoY Change -19.21% -7.35%
SHAREHOLDERS EQUITY
Retained Earnings -$1.100B -$1.800B
YoY Change -38.89% 59.75%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.003B $849.2M
YoY Change
Total Liabilities & Shareholders Equity $2.081B $945.0M
YoY Change 120.18% -33.59%

Cashflow Statement

Concept 2021 Q1 2020 Q1
OPERATING ACTIVITIES
Net Income -$95.76M -$126.7M
YoY Change -24.44% -22.44%
Depreciation, Depletion And Amortization $2.600M $700.0K
YoY Change 271.43% 75.0%
Cash From Operating Activities -$109.1M -$136.7M
YoY Change -20.2% -8.83%
INVESTING ACTIVITIES
Capital Expenditures $276.0K
YoY Change -78.04%
Acquisitions
YoY Change
Other Investing Activities -$658.8M $206.5M
YoY Change -419.03% -175.45%
Cash From Investing Activities -$658.8M $206.3M
YoY Change -419.39% -175.03%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 5.623M 3.160M
YoY Change 77.94% -99.45%
NET CHANGE
Cash From Operating Activities -109.1M -136.7M
Cash From Investing Activities -658.8M 206.3M
Cash From Financing Activities 5.623M 3.160M
Net Change In Cash -762.3M 72.74M
YoY Change -1147.96% -51.94%
FREE CASH FLOW
Cash From Operating Activities -$109.1M -$136.7M
Capital Expenditures $276.0K
Free Cash Flow -$137.0M
YoY Change -9.41%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q1 us-gaap Lessor Operating Lease Option To Extend
LessorOperatingLeaseOptionToExtend
true
CY2021Q1 sage Share Based Compensation Arrangement By Share Based Payment Award Award Cliff Vesting Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardCliffVestingPeriod
P1Y
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-651000
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.64
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-96507000
CY2021Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
708000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
129072000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-95764000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
21976000
CY2021Q1 sage Premium On Marketable Securities
PremiumOnMarketableSecurities
9459000
CY2021Q1 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-1325000
CY2021Q1 us-gaap Depreciation
Depreciation
2582000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
262000
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
24766000
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3160000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
72739000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
900519000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
201811000
CY2021Q1 sage Lease Asset De Recognized Upon Lease Cancellation
LeaseAssetDeRecognizedUponLeaseCancellation
3733000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
944655000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
367000
CY2020Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2793000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
849206000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-95764000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
2003276000
CY2021Q1 us-gaap Deferred Revenue Additions
DeferredRevenueAdditions
606100000
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1100000000
CY2021Q1 us-gaap Proceeds From Collaborators
ProceedsFromCollaborators
1000000000.0
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10024525
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
4743725
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
31110000
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
58374219
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
35000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-95764000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-95764000
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-651000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-96415000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-658816000
CY2021Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
5623000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5623000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-762279000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1662798000
CY2020Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
15000
CY2021Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-651000
CY2021Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. <span style="Background-color:#FFFFFF;color:#212529;">The full extent to which the COVID-19 pandemic may directly or indirectly impact the Company’s business, results of operations and financial condition, including sales, expenses, reserves and allowances, manufacturing, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including: the </span><span style="color:#000000;">success of the roll-out of vaccines for COVID-19; the length, location and frequency of surges or waves of COVID-19 cases</span><span style="Background-color:#FFFFFF;color:#212529;"> and the duration of the pandemic, even after the vaccines become readily available to all adults; </span><span style="color:#000000;">the extent to which variants of the virus that causes COVID-19 negatively impact vaccination and other efforts to control the pandemic; the duration and severity of any continued precautionary measures taken to curb the spread of COVID-19; and the timing and success of return to normal business operations across the U.S</span><span style="Background-color:#FFFFFF;color:#212529;">. The Company has made estimates of the impact of the COVID-19 pandemic within its condensed consolidated financial statements, and there may be changes to those estimates in future periods. </span>Actual results could differ from those estimates.</p>
CY2020Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
438467000
CY2020Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
2099549000
CY2021Q1 sage Fair Value Assets Transfers Among Level1 Level2 And Level3 Amount
FairValueAssetsTransfersAmongLevel1Level2AndLevel3Amount
0
CY2020Q1 sage Fair Value Assets Transfers Among Level1 Level2 And Level3 Amount
FairValueAssetsTransfersAmongLevel1Level2AndLevel3Amount
0
CY2021Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
1105003000
CY2021Q1 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
1104767000
CY2021Q1 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
2004017000
CY2020Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
1661082000
CY2021Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
222000
CY2021Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
458000
CY2021Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
1104767000
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
438052000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
451000
CY2021Q1 sage Marketable Securities Held To Maturity Fair Value
MarketableSecuritiesHeldToMaturityFairValue
239200000
CY2021Q1 sage Loss On Marketable Securities Held To Maturity Fair Value
LossOnMarketableSecuritiesHeldToMaturityFairValue
219000000.0
CY2021Q1 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2020 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2021Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8825000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
13843000
CY2021Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4652000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7088000
CY2021Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4173000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6755000
CY2021Q1 us-gaap Depreciation
Depreciation
2600000
CY2020Q1 us-gaap Depreciation
Depreciation
700000
CY2021Q1 us-gaap Property Plant And Equipment Gross Period Increase Decrease
PropertyPlantAndEquipmentGrossPeriodIncreaseDecrease
-1800000
CY2021Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Period Increase Decrease
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentPeriodIncreaseDecrease
-1800000
CY2021Q1 sage Accrued Research And Development Costs
AccruedResearchAndDevelopmentCosts
39276000
CY2020Q4 sage Accrued Research And Development Costs
AccruedResearchAndDevelopmentCosts
34398000
CY2021Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3640000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
14769000
CY2021Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
7817000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
5184000
CY2021Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
687000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
500000
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
51420000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
54851000
CY2021Q1 us-gaap Lessor Operating Lease Renewal Term
LessorOperatingLeaseRenewalTerm
P5Y
CY2019Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5300000
CY2021Q1 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P3Y
CY2021Q1 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2022-01-31
CY2020Q2 sage Remaining Amount Of Lease Write Off
RemainingAmountOfLeaseWriteOff
2300000
CY2021Q1 us-gaap Restricted Cash
RestrictedCash
700000
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
550890
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
0
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
0
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
0
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
1286175
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-95764000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-126740000
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
58374219
CY2020Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
51908760
CY2021Q1 us-gaap Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
0
CY2020Q1 us-gaap Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
0
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58374219
CY2020Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
51908760
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
21976000
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
21976000
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
31110000
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
54.93
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
46.44
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.64
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.44
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8270344
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8180719

Files In Submission

Name View Source Status
0001564590-21-022988-index-headers.html Edgar Link pending
0001564590-21-022988-index.html Edgar Link pending
0001564590-21-022988.txt Edgar Link pending
0001564590-21-022988-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gmksagnqbviq000001.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
sage-10q_20210331.htm Edgar Link pending
sage-10q_20210331_htm.xml Edgar Link completed
sage-20210331.xsd Edgar Link pending
sage-20210331_cal.xml Edgar Link unprocessable
sage-20210331_def.xml Edgar Link unprocessable
sage-20210331_lab.xml Edgar Link unprocessable
sage-20210331_pre.xml Edgar Link unprocessable
sage-ex101_175.htm Edgar Link pending
sage-ex311_6.htm Edgar Link pending
sage-ex312_7.htm Edgar Link pending
sage-ex321_8.htm Edgar Link pending
Show.js Edgar Link pending